Jacob-S. Seeler

Jacob-S. Seeler

Auto-generated profile, based on publicly available information

Jacob-S. Seeler

Nuclear Organization and Oncogenesis Unit , Department of Cell Biology and Infection, Institut Pasteur, Université Paris Cité, 75015 Paris

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in Cell
Verified
Journal Article
Closed access
APAndrea Pichler
Andrea Pichler
AGAndreas Gast
Andreas Gast
JSJacob S. Seeler
Jacob S. Seeler
ADAnne Dejean
Anne Dejean
FMFrauke Melchior
Frauke Melchior

1 September 2003 in Nature Reviews Molecular Cell Biology
Verified
Journal Article
Closed access
JSJacob-S. Seeler
Jacob-S. Seeler
ADAnne Dejean
Anne Dejean

30 January 2017 in Nature Reviews Cancer
Verified
Journal Article
Closed access
JSJacob-Sebastian Seeler
Jacob-Sebastian Seeler
ADAnne Dejean
Anne Dejean

1 October 2002 in EMBO Reports
Verified
Journal Article
Open access
PDF file
Christian MuchardtChristian Muchardt
Christian Muchardt
MGMarie Guillemé
Marie Guillemé
JSJacob‐S Seeler
Jacob‐S Seeler
DTDidier Trouche
Didier Trouche
ADAnne Dejean
Anne Dejean
MYMoshe Yaniv
Moshe Yaniv
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 May 2000 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
Stefan MüllerStefan Müller
Stefan Müller
MBMichael Berger
Michael Berger
FLFrançois Lehembre
François Lehembre
JSJacob-S. Seeler
Jacob-S. Seeler
Ygal HauptYgal Haupt
Ygal Haupt
ADAnne Dejean
Anne Dejean
The ubiquitin-related SUMO-1 molecule has been shown recently to modify covalently a number of cellular proteins including IκBα. SUMO-1 modification was found to antagonize IκBα ubiquitination and protect it from degradation. Here we identify the transcription factors c-Jun and p53, two well known targets of ubiquitin, as new substrates for SUMO-1 both in vitro and in vivo. In contrast to ubiquitin, SUMO-1 preferentially targets a single lysine residue in c-Jun (Lys-229), and the abrogation of SUMO-1 modification does not compromise its ubiquitination. Activation of Jun NH2-terminal kinases, which induces a reduction in c-Jun ubiquitination, similarly decreases SUMO-1 modification. Accordingly, loss of the two major Jun NH2-terminal kinase phosphorylation sites in c-Jun, Ser-63 and Ser-73, greatly enhances conjugation by SUMO-1. A SUMO-1- deficient c-JunK229R mutant shows an increased transactivation potential on an AP-1-containing promoter compared with wild-type c-Jun, suggesting that SUMO-1 negatively regulates c-Jun activity. As with c-Jun, SUMO-1 modification of p53 is abrogated by phosphorylation but remains unaltered upon chemical damage to DNA or Mdm2-mediated ubiquitination. The SUMO-1 attachment site in p53 (Lys-386) resides within a region known to regulate the DNA binding activity of the protein. A p53 mutant, defective for SUMO-1 conjugation, shows unaltered ubiquitination but has a slightly impaired apoptotic activity, indicating that modification by SUMO-1 might be important for the full biological activity of p53. Taken together, these data provide a first link between the SUMO-1 conjugation pathway and the regulation of transcription factors.

3 June 2002 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
OKOlivier Kirsh
Olivier Kirsh
JSJacob‐S. Seeler
Jacob‐S. Seeler
APAndrea Pichler
Andrea Pichler
AGAndreas Gast
Andreas Gast
Stefan MüllerStefan Müller
Stefan Müller
ADAnne Dejean
Anne Dejean
Transcriptional repression mediated through histone deacetylation is a critical component of eukaryotic gene regulation. Here we demonstrate that the class II histone deacetylase HDAC4 is covalently modified by the ubiquitin‐related SUMO‐1 modifier. A sumoylation‐deficient point mutant (HDAC4‐K559R) shows a slightly impaired ability to repress transcription as well as reduced histone deacetylase activity. The ability of HDAC4 to self‐aggregate is a prerequisite for proper sumoylation in vivo . Calcium/calmodulin‐dependent protein kinase (CaMK) signalling, which induces nuclear export, abrogates SUMO‐1 modification of HDAC4. Moreover, the modification depends on the presence of an intact nuclear localization signal and is catalysed by the nuclear pore complex (NPC) RanBP2 protein, a factor newly identified as a SUMO E3 ligase. These findings suggest that sumoylation of HDAC4 takes place at the NPC and is coupled to its nuclear import. Finally, modification experiments indicate that the MEF2‐interacting transcription repressor (MITR) as well as HDAC1 and ‐6 are similarly SUMO modified, indicating that sumoylation may be an important regulatory mechanism for the control of transcriptional repression mediated by both class I and II HDACs.